C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say
Executive Summary
ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert